IPO Issue Details
Issue Price / Price Band₹218 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size65 Shares per Lot
Total Issue Size2,98,00,000 shares (aggregating up to ₹649.64 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenWed, 16 Mar 2016
Subscription CloseFri, 18 Mar 2016
Anchor AllotmentTue, 15 Mar 2016
Basis of AllotmentThu, 24 Mar 2016
Initiation of RefundsFri, 25 Mar 2016
Credit of Shares to DematFri, 25 Mar 2016
Listing DateWed, 30 Mar 2016
UPI Mandate Deadline2016-03-18
Application & Investment Details
Retail — Min (1 Lots)₹14,170 — 65 shares
Retail — Max (13 Lots)₹184,210 (13 Lots)
HNI — Min (15 Lots)₹2,12,550 — 975 shares
Pre-IPO Promoter Holding7,34,75,986 shares
Post-IPO Promoter Holding8,50,75,986 shares
Fresh Issue Shares1,16,00,000 shares (aggregating up to ₹252.88 Cr)
Offer for Sale Shares1,82,00,000 shares of ₹10 (aggregating up to ₹396.76 Cr)
About Healthcare Global Enterprises Ltd.
Healthcare Global Enterprises Ltd (HCG) is Bangalore India based provider of speciality healthcare in India focused on cancer and fertility.HCG operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed. HCG also operates fertility centres under the 'Milann' brand.As of December 31, 2015, HCG network consisted of 14 comprehensive cancer centres, including centre of excellence in Bengaluru, three freestanding diagnostic centres and one day care chemotherapy centre across India.HCG acquired 50.10% equity in BACC Healthcare in 2013 which operates fertility centres under the Milann brand, through itself and its wholly-owned subsidiary, DKR Healthcare. HCG now operate four Milann fertility centres in Bengaluru. BACC Healthcare is led by a team of qualified and experienced fertility specialists. Its founder, Dr. Kamini Rao has a successful track record of over 25 years of providing fertility treatments. Milann fertility centres provide comprehensive reproductive medicine services, including assisted reproduction, gynaecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment.Under Triesta brand, HCG provide clinical reference laboratory services in India with a specialisation in oncology, including molecular diagnostic services and genomic testing. Triesta central reference laboratory is located in centre of excellence in Bengaluru.Strengths of the Company:1. Largest provider of cancer care in India with a proven track record2. High quality cancer care provided at a competitive price3. Entry into high potential fertility business4. Strong management team with successful track record5. Highly skilled specialist physicians6. 'hub and spoke' business model and partnership arrangements
Objects of the Issue
Healthcare Global Enterprises Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
1 Purchase of medical equipment
42.21
2
2 Investment in IT software, services and hardware
30.19
3
3 Pre-payment of debt
147.05
4
4 General corporate purposes
19.77
Shareholding & Lock-in
Pre-IPO Promoter Holding
7,34,75,986 shares
Post-IPO Promoter Holding
8,50,75,986 shares